Investor Exit Overshadows Regulatory Wins for Bayer Shares

Bayer's stock recovery halted by a €318M shareholder exit, overshadowing key Japanese drug approvals for Eylea and a new MRI contrast agent.

Positive regulatory developments from Japan for pharmaceutical and agricultural giant Bayer were eclipsed in market trading by a significant divestment from a major shareholder. This substantial sale has interrupted the stock's recent attempts to stage a recovery.

A Major Shareholder Exits Position

Market sentiment turned negative following news that investment firm Inclusive Capital Partners decided to exit its stake. The firm, founded by Jeff Ubben, sold approximately 8.5 million Bayer shares via JPMorgan at a price of 37.45 euros each. The transaction, with a total volume of around 318 million euros, exerted noticeable downward pressure on the share price.

This sale represented a loss, as the shares were disposed of at a price roughly 25 percent below the level at which Inclusive Capital initially built its position in January 2023. The market's reaction was swift. After briefly trading above the key 100-day moving average—a technical indicator currently at 38.80 euros—the stock retreated. It closed at 38.16 euros, settling once more below this watched medium-term trend line.

Japanese Approvals Offer Operational Momentum

Despite the market's focus on the sale, Bayer announced two significant regulatory approvals in Japan. The country's Ministry of Health granted authorization for a higher 8-milligram dosage of the eye drug Eylea, used to treat macular edema. Clinical data indicates this formulation requires fewer injections for patients compared to the standard dose. Bayer projects this higher-dose variant could constitute up to 70 percent of the Eylea portfolio by 2026.

In a separate development, the company received the world's first approval for its MRI contrast agent, Ambelvist, in Japan. The product achieves comparable image quality while using 60 percent less gadolinium. Bayer is now advancing parallel approval processes for this agent in the United States, China, and the European Union.

Upcoming Catalysts and Financial Pressure

Investors are now looking ahead to a packed schedule of events in the coming months that are expected to influence the stock:

• April 24, 2026: Annual General Meeting
• April 27, 2026: Start of Supreme Court hearings related to the glyphosate litigation
• May 12, 2026: First-quarter earnings release
• Second half of June 2026: Expected Supreme Court ruling

Beyond these critical legal milestones, the quarterly results in May will be scrutinized for the company's guidance on free cash flow. This metric is anticipated to be deeply negative for the current year, pressured by expected legal expenses of approximately five billion euros.